浙江巨化股份有限公司董事会 九届二十三次（通讯方式） 会议决议公告

Core Viewpoint - Zhejiang Juhua Co., Ltd. has announced a significant impairment provision of 320.89 million yuan for fixed assets in 2025, reflecting the company's efforts to accurately represent its asset status and optimize its asset structure [1][5][6]. Group 1: Impairment Provision Details - The impairment provision includes 99.55 million yuan for the cyclohexanone unit, 206.71 million yuan for the caprolactam unit, and 14.63 million yuan for the diketoxime unit [5]. - The cyclohexanone unit, operational since July 1987, has a net book value of 111.73 million yuan as of December 31, 2025 [2]. - The caprolactam unit, which began operations in 2014 and was expanded in 2020, has a net book value of 232.10 million yuan as of December 31, 2025 [2]. - The diketoxime unit, operational since 2019, has a net book value of 15.63 million yuan as of December 31, 2025 [2]. Group 2: Reasons for Impairment - The cyclohexanone unit faces significant operational challenges due to outdated technology and high production costs, especially under increasing environmental regulations [3]. - The caprolactam unit has been operating at a loss due to market competition and low downstream demand, making recovery to previous profit levels unlikely [3][4]. - The diketoxime unit has been out of production since September 2025 due to changes in market supply and demand [4]. Group 3: Financial Impact - The impairment provision is expected to reduce the company's net profit attributable to shareholders by 320.89 million yuan for the year 2025 [5]. - The provision aligns with industry policies and accounting standards, ensuring that the financial statements accurately reflect the company's asset values [6]. Group 4: Performance Forecast - The company anticipates a net profit attributable to shareholders of between 3.54 billion yuan and 3.94 billion yuan for 2025, representing an increase of 1.58 billion yuan to 1.98 billion yuan compared to the previous year [8][10]. - The expected growth in net profit is attributed to the recovery in prices of core products, particularly fluorinated refrigerants, and stable production and sales volumes [14][15].